New: Introducing the Finviz Futures Map

Opus Genetics, Inc.

Contributing Author

Recent Articles by Opus Genetics, Inc.

7 hours	Opus Genetics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference IRD GlobeNewswire
Sep-02	Opus Genetics Appoints Rob Gagnon as Chief Financial Officer IRD GlobeNewswire
Aug-27	Opus Genetics Inherited Retinal Disease Programs Featured at Medical and Industry Conferences in September IRD GlobeNewswire
Aug-18	Opus Genetics Announces FDA Clearance of IND Application for Gene Therapy Candidate OPGx-BEST1 IRD GlobeNewswire
Aug-13	Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update IRD GlobeNewswire
Aug-05	Opus Genetics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference IRD GlobeNewswire
Jul-23	Opus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood Blindness IRD GlobeNewswire
Jul-03	Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) IRD GlobeNewswire
Jun-26	Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia IRD GlobeNewswire
Jun-23	Opus Genetics Awarded Non-Dilutive Funding from the RD Fund to Support Preclinical Development of OPGx-MERTK Program IRD GlobeNewswire
Jun-02	Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions IRD GlobeNewswire
May-15	Opus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate Update IRD GlobeNewswire
May-12	Opus Genetics Announces Presentations on Inherited Retinal Disease Programs at Medical Conferences in May IRD GlobeNewswire
May-06	Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy Candidate IRD GlobeNewswire
May-05	Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful Vision IRD GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.